# Avance Nerve Graft

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/avance-nerve-graft
Canonical HTML page: https://getbiobrief.com/entity/avance-nerve-graft

## Recent coverage (1 stories)

### DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth
2026-03-22 04:25:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Full story: https://getbiobrief.com/story/dafna-capital-trims-axogen-stake-71-surge

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.